Summary & Overview
CPT 81161: DMD Gene Deletion/Duplication Analysis
CPT code 81161 represents a molecular diagnostic laboratory test that analyzes deletions and possible duplications in the dystrophin (DMD) gene. This genetic assay is clinically significant for diagnosing Duchenne and Becker muscular dystrophies and for informing genetic counseling, family planning, and eligibility for targeted therapies. Nationally, accurate billing and coverage for DMD genetic testing affect access to diagnosis and subsequent care pathways for affected individuals.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication summarizes payer coverage patterns, common billing considerations, and where available, reimbursement benchmarks and policy updates that influence test utilization.
Readers will learn what CPT code 81161 denotes, the typical laboratory and clinical contexts in which the test is performed, and how major payers approach coverage and coding for DMD deletion/duplication analysis. The report also outlines common modifiers reported with laboratory services and highlights areas where policy updates or payer-specific rules commonly affect claim adjudication. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 81161 describes a laboratory molecular diagnostic procedure that analyzes specific changes involving deleted, or possibly repeated, nucleotide sequences in the dystrophin (DMD) gene. The service reflects the technical laboratory analysis performed by a lab analyst to detect exon-level deletions or duplications in the DMD gene.
Service type: Molecular diagnostic laboratory test (genetic testing / deletion/duplication analysis)
Typical site of service: Clinical diagnostic laboratory or reference molecular genetics laboratory
Clinical & Coding Specifications
Clinical Context
A typical patient is a male child or young adult presenting with progressive muscle weakness, delayed motor milestones, frequent falls, and elevated serum creatine kinase. Clinical evaluation by a pediatric neurologist or geneticist includes detailed family history and physical exam suggesting dystrophinopathy. A blood sample is sent to a molecular genetics laboratory for deletion/duplication analysis of the dystrophin (DMD) gene using techniques such as multiplex ligation-dependent probe amplification (MLPA) or comparative genomic hybridization. The lab analyst performs the technical assay described by 81161, identifies exon deletions or duplications, and generates a technical report. The geneticist interprets results in the clinical context, informs the family, and documents findings in the medical record. Typical sites of service include outpatient hospital laboratories, independent clinical laboratories, and hospital-based molecular pathology labs. Common care pathway steps include sample collection, specimen accessioning, DNA extraction, targeted DMD gene testing (technical component 81161), interpretation, and issuance of a finalized genetic report to the ordering clinician.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the interpretation/reporting (professional) portion separate from the technical lab work. |